Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design.
Saved in:
| Title: | Mycobacterium tuberculosis KasA as a drug target: Structure-based inhibitor design. |
|---|---|
| Authors: | Rudraraju RS; Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ, United States., Daher SS; Department of Pharmacology, Physiology, and Neuroscience, New Jersey Medical School, Rutgers University, Newark, NJ, United States., Gallardo-Macias R; Department of Pharmacology, Physiology, and Neuroscience, New Jersey Medical School, Rutgers University, Newark, NJ, United States., Wang X; Department of Immunology and Infectious Diseases, Harvard University T.H. Chan School of Public Health, Boston, MA, United States., Neiditch MB; Department of Microbiology, Biochemistry and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, NJ, United States., Freundlich JS; Department of Pharmacology, Physiology, and Neuroscience, New Jersey Medical School, Rutgers University, Newark, NJ, United States.; Department of Medicine, Center for Emerging and Re-emerging Pathogens, New Jersey Medical School, Rutgers University, Newark, NJ, United States. |
| Source: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2022 Sep 15; Vol. 12, pp. 1008213. Date of Electronic Publication: 2022 Sep 15 (Print Publication: 2022). |
| Publication Type: | Journal Article; Review; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
